EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY 4.0

Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents

David J Jackson iD, Michael E Wechsler, Guy Brusselle, Roland Buhl

Allergy · 2024-11 · 79 (11) · 2943-2952

DOI: 10.1111/all.16346 ↗

At a glance

Übersichtsarbeit in Allergy, published online on 2024-10-12. Written by David J Jackson and 3 co-authors. Institution: Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, UK. Major MEDLINE topics: Interleukin-5, Asthma, Receptors, Interleukin-5, Anti-Asthmatic Agents. Cited 42 times so far (Crossref); 66 references. The full text is freely available (open access, CC BY 4.0). Funded by: AstraZeneca.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Eosinophilic asthma is characterized by frequent exacerbations, poor symptom control and accelerated lung function decline. It is now recognized that the immune response underlying eosinophilic asthma involves a complex network of interconnected pathways from both the adaptive and innate immune systems. Within this response, interleukin‐5 (IL‐5) plays a central role in eosinophil differentiation, activation and survival and has emerged as a key target for therapies treating severe asthma. The monoclonal antibodies mepolizumab and reslizumab target the ligand IL‐5, preventing its interaction with eosinophils; in contrast, benralizumab binds to the IL‐5 receptor (IL‐5R), preventing IL‐5 from binding and leading to substantially greater eosinophil reduction by enhanced antibody‐dependent cell‐mediated cytotoxicity. Although no direct head‐to‐head clinical trials of asthma have been published to formally evaluate the clinical significance of these different therapeutic approaches, the potential benefits of partial versus complete eosinophil depletion continue to remain an important area of study and debate. Here, we review the existing real‐world and clinical study data of anti‐IL‐5/anti‐IL‐5R therapies in severe eosinophilic asthma.

Subjects

MeSH terms (MEDLINE)

Interleukin-5AsthmaReceptors, Interleukin-5Anti-Asthmatic AgentsEosinophilsHumansSignal TransductionMolecular Targeted TherapyTreatment OutcomeAntibodies, Monoclonal, HumanizedEosinophiliaAntibodies, MonoclonalAnimals

Author keywords

IL‐5IL‐5Rasthmabenralizumabeosinophilmepolizumabreslizumab

Substances

Interleukin-5Receptors, Interleukin-5Anti-Asthmatic AgentsIL5 protein, humanAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Authors and institutions

  • Guy's Severe Asthma Centre, Guy's and St Thomas' NHS Trust, London, UK.
  • School of Immunology & Microbial Sciences, King's College London, London, UK.
  • Department of Medicine, National Jewish Health, Denver, Colorado, USA.
  • Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
  • Pulmonary Department, Mainz University Hospital, Mainz, Germany.

ORCID profiles: David J Jackson

Funding

  • AstraZeneca

Cite

APA

Jackson, D. J., Wechsler, M. E., Brusselle, G., & Buhl, R. (2024). Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents. Allergy, 79(11), 2943-2952. https://doi.org/10.1111/all.16346

Vancouver

Jackson DJ, Wechsler ME, Brusselle G, Buhl R. Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents. Allergy. 2024;79(11):2943-2952. doi:10.1111/all.16346

BibTeX
@article{Jackson2024,
  author = {Jackson, David J and Wechsler, Michael E and Brusselle, Guy and Buhl, Roland},
  title = {Targeting the IL ‐5 pathway in eosinophilic asthma: A comparison of anti‐ IL ‐5 versus anti‐ IL ‐5 receptor agents},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {11},
  pages = {2943--2952},
  doi = {10.1111/all.16346}
}
Start for free →